Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 40.74% is 17% below its 5-year average of 48.98%, near the high end of its 5-year range (-1008.43%–70.56%).
24.90% below its 12-month average of 54.25%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 70.56%.
EBITDA MARGIN
40.74%
EBITDA MARGIN AVG TTM
54.25%
EBITDA MARGIN AVG 3Y
41.19%
EBITDA MARGIN AVG 5Y
48.98%
EBITDA MARGIN AVG 10Y
21.04%
EBITDA MARGIN AVG 15Y
-22.31%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-24.90%
CURRENT VS 3Y AVG
-1.10%
CURRENT VS 5Y AVG
-16.82%
CURRENT VS 10Y AVG
+93.60%
CURRENT VS 15Y AVG
+282.60%
CURRENT VS 20Y AVG
N/A
Ironwood Pharmaceuticals, Inc.
Market Cap
$596.72M
EBITDA Margin
40.74%
TTM Avg
54.25%
3Y Avg
41.19%
5Y Avg
48.98%
Market Cap
$605.22M
EBITDA Margin
-20.76%
TTM Avg
-19.02%
3Y Avg
-15.62%
5Y Avg
12.71%
Market Cap
$580.22M
EBITDA Margin
-3.28%
TTM Avg
-4.19%
3Y Avg
-6.19%
5Y Avg
-9.77%
Market Cap
$612.34M
EBITDA Margin
-5.39%
TTM Avg
-5.12%
3Y Avg
-17.61%
5Y Avg
-12.23%
Market Cap
$563.97M
EBITDA Margin
-155.10%
TTM Avg
-103.66%
3Y Avg
-79.43%
5Y Avg
-77.63%
Market Cap
$562.50M
EBITDA Margin
52.98%
TTM Avg
1.13%
3Y Avg
-15499.35%
5Y Avg
-14628.26%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. (IRWD) | $596.72M | 40.74% | 54.25% | 41.19% | 48.98% |
| Fulgent Genetics, Inc. (FLGT)vs › | $605.22M | -20.76% | -19.02% | -15.62% | 12.71% |
| OrthoPediatrics Corp. (KIDS)vs › | $580.22M | -3.28% | -4.19% | -6.19% | -9.77% |
| AngioDynamics, Inc. (ANGO)vs › | $612.34M | -5.39% | -5.12% | -17.61% | -12.23% |
| Climb Bio, Inc. (CLYM)vs › | $624.17M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $563.97M | -155.10% | -103.66% | -79.43% | -77.63% |
| CorMedix Inc. (CRMD)vs › | $562.50M | 52.98% | 1.13% | -15499.35% | -14628.26% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $569.15M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $635.62M | N/A | N/A | N/A | N/A |
Gross Margin
99.8%
EBITDA Margin
40.7%
Operating Margin
40.1%
Net Margin
33.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 70.56% |
| 2026-03-31 | 68.52% |
| 2025-12-31 | 14.70% |
| 2025-09-30 | 64.03% |
| 2025-06-30 | 53.42% |
| 2025-03-31 | -69.58% |
| 2024-12-31 | 35.32% |
| 2024-09-30 | 28.54% |
| 2024-06-30 | 27.00% |
| 2024-03-31 | 15.40% |
| 2023-12-31 | 32.43% |
| 2023-09-30 | 43.18% |
| 2023-06-30 | -1008.43% |
| 2023-03-31 | 58.03% |
| 2022-12-31 | 64.09% |
| 2022-09-30 | 63.36% |
| 2022-06-30 | 57.61% |
| 2022-03-31 | 59.68% |
| 2021-12-31 | 48.62% |
| 2021-09-30 | 63.16% |
| 2021-06-30 | 62.96% |
| 2021-03-31 | 51.56% |
| 2020-12-31 | 44.40% |
| 2020-09-30 | 45.85% |
| 2020-06-30 | 37.29% |
| 2020-03-31 | 17.40% |
| 2019-12-31 | 39.95% |
| 2019-09-30 | 52.65% |
| 2019-06-30 | 21.94% |
| 2019-03-31 | -78.11% |
| 2018-12-31 | 5.56% |
| 2018-09-30 | -253.56% |
| 2018-06-30 | -44.93% |
| 2018-03-31 | -46.84% |
| 2017-12-31 | 27.85% |
| 2017-09-30 | -18.17% |
| 2017-06-30 | -59.41% |
| 2017-03-31 | -69.73% |
| 2016-12-31 | -3.43% |
| 2016-09-30 | -37.93% |
| 2016-06-30 | -26.22% |
| 2016-03-31 | 1.31% |
| 2015-12-31 | -5.68% |
| 2015-09-30 | -59.13% |
| 2015-06-30 | -140.06% |
| 2015-03-31 | -87.02% |
| 2014-12-31 | -79.25% |
| 2014-09-30 | -198.43% |
| 2014-06-30 | -760.73% |
| 2014-03-31 | -282.51% |
| 2013-12-31 | -867.74% |
| 2013-09-30 | -1084.37% |
| 2013-06-30 | -590.82% |
| 2013-03-31 | -2643.47% |
| 2012-12-31 | -152.32% |
| 2012-09-30 | 52.52% |
| 2012-06-30 | -260.37% |
| 2012-03-31 | -269.07% |
| 2011-12-31 | -13.55% |
| 2011-09-30 | -158.21% |
| 2011-06-30 | -142.50% |
| 2011-03-31 | -160.29% |
| 2010-12-31 | -64.86% |
| 2010-09-30 | -162.55% |
| 2010-06-30 | -144.33% |
| 2010-03-31 | -164.88% |
| 2009-12-31 | -264.56% |
| 2009-09-30 | -45.77% |
| 2009-06-30 | -260.79% |
| 2009-03-31 | -331.39% |
| 2008-12-31 | -313.63% |
